Latest news with #GP2
Miami Herald
5 days ago
- Business
- Miami Herald
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interview in its entirety at: In an exclusive previously recorded interview, Snehal Patel, CEO of Greenwich LifeSciences, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to prevent breast cancer recurrences through GLSI-100, a novel breast cancer vaccine immunotherapy combining the HER2-derived GP2 peptide with GM-CSF. Patel highlights the promising results from a prior Phase II trial showing no metastatic recurrences in immunized patients and details the global expansion of the ongoing Phase III FLAMINGO-01 trial, now active at more than 120 sites across the U.S. and Europe. He also outlines the Company's strategy to accelerate commercialization through advanced manufacturing readiness and strong academic partnerships, positioning GLSI-100 as a potential game-changer in the HER2-positive breast cancer treatment landscape. GLSI is a client of RedChip Companies. Please read our full disclosure at About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
Yahoo
29-05-2025
- Business
- Yahoo
Rune Labs and Parkinson's Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson's Disease
Bringing together Rune Labs' StrivePD AI software and PD GENEration from Parkinson's Foundation, the Global Parkinson's Genetics Program (GP2) looks to accelerate therapeutic development and deployment SAN FRANCISCO, May 29, 2025--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for Parkinson's disease (PD), today announced the launch of a clinical program with Parkinson's Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson's patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs' StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson's Foundation. The GP2 program, one of three Aligning Science Across Parkinson's (ASAP) initiative-funded programs implemented by The Michael J. Fox Foundation, aims to improve understanding of the genetic architecture of PD by integrating ancestrally diverse populations to address a large gap in scientists' knowledge about the disease. Led by Dr. Andrew B. Singleton and Dr. Cornelis Blauwendraat, GP2's partnership with the Parkinson's Foundation will further increase the ancestral diversity of global PD genetic data. Despite a growing global patient population—expected to exceed 25 million by 2050—people with Parkinson's still need advances in diagnostics and treatments, despite progress over the past two decades. The study is intended to help address this by identifying biological and digital signatures of the disease that can support earlier diagnosis, more precise patient stratification for clinical trials, and the development of better-targeted treatment strategies. Leveraging StrivePD, participants will use an iPhone and Apple Watch to track motor symptoms passively, including tremor and dyskinesia, along with self-reported activities like mood and medications, while completing remote surveys and rating scales on their health and Parkinson's symptoms. Through PD GENEration, participants will undergo genetic testing and counseling by providing a blood sample that will be used to test for clinically validated PD-related genetic variants. The study may help participants determine eligibility for genetically based clinical studies. "We believe that there is significant potential to advance Parkinson's research by combining genetic insights with real-world data derived from AI-driven platforms like StrivePD to define disease subtypes. As trials become more precise, we can leverage data from this new study to reduce the noise, match patients to the right interventions, and generate stronger evidence to support the development of much-needed personalized treatments. If you carry a gene mutation, you shouldn't be treated like every other patient. This study could move us from 'average-patient' dosing to genome-matched therapy recommendations," said Brian Pepin, CEO of Rune Labs. StrivePD closes the gap in Parkinson's care caused by infrequent specialist visits and unpredictable symptoms. Through AI-driven monitoring, the software care ecosystem combines Apple Watch data with the StrivePD app to track FDA-cleared metrics like tremor and dyskinesia, plus self-reported daily routines, to deliver real-time insights and proactive treatment guidance. By providing insights into symptoms at all hours of the day, StrivePD helps patients manage symptoms between visits, improve medication adherence, and avoid unnecessary ER trips, allowing them to take control of their disease and ease the pressure on the healthcare system. Using AI and extensive real-world patient data, StrivePD is also changing how neurological clinical trials are designed, helping improve predictive accuracy and reducing trial failures. PD GENEration from the Parkinson's Foundation is an international research initiative offering genetic testing and counseling at no cost to individuals diagnosed with PD. Since its inception in 2019, PD GENEration has enrolled over 24,000 people living with PD (PwP) across North, Central, and South America, the Caribbean, and Israel. PD GENEration's mission is to help PwP better understand their genetic link to PD and manage their PD treatment and care, contribute to the scientific understanding of PD now and into the future, and accelerate enrollment into clinical trials by empowering PwP and clinicians around the importance of genetics. "We created PD GENEration to empower those with Parkinson's and their families to know more about their disease, accelerate clinical trials [that may one day halt Parkinson's], and drive forward research into the complex genetic factors that contribute to Parkinson's severity, progression, and treatment response," said James Beck, PhD and Chief Scientific Officer of the Parkinson's Foundation. "This new study with Rune Labs brings in powerful digital insights that can help us decode Parkinson's even further and speed up the path toward more effective treatments, and one day, a cure. Together, we can make better lives for those living with PD." Initial genotype-response findings are expected in 2026, with anonymized results made available to researchers through the GP2 data repository to accelerate future studies. About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit and About Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). About the Global Parkinson's Genetics Program The Global Parkinson's Genetics Program (GP2) is an ambitious program focused on improving our understanding of the genetic architecture of the PD spectrum in a global context. This work will help address the most pressing needs of the global PD community, accelerating development and deployment of better PD therapies. GP2 is made up of member organizations around the world that are coming together to create a global research community. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Disease Research. About Parkinson's Disease Affecting an estimated one million Americans, Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson's and nearly 90,000 new cases are diagnosed each year in the U.S. View source version on Contacts Media Contact Consort Partners for Rune Labsrunelabs@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Rune Labs and Parkinson's Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson's Disease
Bringing together Rune Labs' StrivePD AI software and PD GENEration from Parkinson's Foundation, the Global Parkinson's Genetics Program (GP2) looks to accelerate therapeutic development and deployment SAN FRANCISCO, May 29, 2025--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for Parkinson's disease (PD), today announced the launch of a clinical program with Parkinson's Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson's patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs' StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson's Foundation. The GP2 program, one of three Aligning Science Across Parkinson's (ASAP) initiative-funded programs implemented by The Michael J. Fox Foundation, aims to improve understanding of the genetic architecture of PD by integrating ancestrally diverse populations to address a large gap in scientists' knowledge about the disease. Led by Dr. Andrew B. Singleton and Dr. Cornelis Blauwendraat, GP2's partnership with the Parkinson's Foundation will further increase the ancestral diversity of global PD genetic data. Despite a growing global patient population—expected to exceed 25 million by 2050—people with Parkinson's still need advances in diagnostics and treatments, despite progress over the past two decades. The study is intended to help address this by identifying biological and digital signatures of the disease that can support earlier diagnosis, more precise patient stratification for clinical trials, and the development of better-targeted treatment strategies. Leveraging StrivePD, participants will use an iPhone and Apple Watch to track motor symptoms passively, including tremor and dyskinesia, along with self-reported activities like mood and medications, while completing remote surveys and rating scales on their health and Parkinson's symptoms. Through PD GENEration, participants will undergo genetic testing and counseling by providing a blood sample that will be used to test for clinically validated PD-related genetic variants. The study may help participants determine eligibility for genetically based clinical studies. "We believe that there is significant potential to advance Parkinson's research by combining genetic insights with real-world data derived from AI-driven platforms like StrivePD to define disease subtypes. As trials become more precise, we can leverage data from this new study to reduce the noise, match patients to the right interventions, and generate stronger evidence to support the development of much-needed personalized treatments. If you carry a gene mutation, you shouldn't be treated like every other patient. This study could move us from 'average-patient' dosing to genome-matched therapy recommendations," said Brian Pepin, CEO of Rune Labs. StrivePD closes the gap in Parkinson's care caused by infrequent specialist visits and unpredictable symptoms. Through AI-driven monitoring, the software care ecosystem combines Apple Watch data with the StrivePD app to track FDA-cleared metrics like tremor and dyskinesia, plus self-reported daily routines, to deliver real-time insights and proactive treatment guidance. By providing insights into symptoms at all hours of the day, StrivePD helps patients manage symptoms between visits, improve medication adherence, and avoid unnecessary ER trips, allowing them to take control of their disease and ease the pressure on the healthcare system. Using AI and extensive real-world patient data, StrivePD is also changing how neurological clinical trials are designed, helping improve predictive accuracy and reducing trial failures. PD GENEration from the Parkinson's Foundation is an international research initiative offering genetic testing and counseling at no cost to individuals diagnosed with PD. Since its inception in 2019, PD GENEration has enrolled over 24,000 people living with PD (PwP) across North, Central, and South America, the Caribbean, and Israel. PD GENEration's mission is to help PwP better understand their genetic link to PD and manage their PD treatment and care, contribute to the scientific understanding of PD now and into the future, and accelerate enrollment into clinical trials by empowering PwP and clinicians around the importance of genetics. "We created PD GENEration to empower those with Parkinson's and their families to know more about their disease, accelerate clinical trials [that may one day halt Parkinson's], and drive forward research into the complex genetic factors that contribute to Parkinson's severity, progression, and treatment response," said James Beck, PhD and Chief Scientific Officer of the Parkinson's Foundation. "This new study with Rune Labs brings in powerful digital insights that can help us decode Parkinson's even further and speed up the path toward more effective treatments, and one day, a cure. Together, we can make better lives for those living with PD." Initial genotype-response findings are expected in 2026, with anonymized results made available to researchers through the GP2 data repository to accelerate future studies. About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit and About Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). About the Global Parkinson's Genetics Program The Global Parkinson's Genetics Program (GP2) is an ambitious program focused on improving our understanding of the genetic architecture of the PD spectrum in a global context. This work will help address the most pressing needs of the global PD community, accelerating development and deployment of better PD therapies. GP2 is made up of member organizations around the world that are coming together to create a global research community. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Disease Research. About Parkinson's Disease Affecting an estimated one million Americans, Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson's and nearly 90,000 new cases are diagnosed each year in the U.S. View source version on Contacts Media Contact Consort Partners for Rune Labsrunelabs@ Sign in to access your portfolio
Business Wire
29-05-2025
- Health
- Business Wire
Rune Labs and Parkinson's Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson's Disease
SAN FRANCISCO--(BUSINESS WIRE)-- Rune Labs, the leader in precision medicine for Parkinson's disease (PD), today announced the launch of a clinical program with Parkinson's Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson's patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs' StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson's Foundation. The GP2 program, one of three Aligning Science Across Parkinson's (ASAP) initiative-funded programs implemented by The Michael J. Fox Foundation, aims to improve understanding of the genetic architecture of PD by integrating ancestrally diverse populations to address a large gap in scientists' knowledge about the disease. Led by Dr. Andrew B. Singleton and Dr. Cornelis Blauwendraat, GP2's partnership with the Parkinson's Foundation will further increase the ancestral diversity of global PD genetic data. Despite a growing global patient population—expected to exceed 25 million by 2050—people with Parkinson's still need advances in diagnostics and treatments, despite progress over the past two decades. The study is intended to help address this by identifying biological and digital signatures of the disease that can support earlier diagnosis, more precise patient stratification for clinical trials, and the development of better-targeted treatment strategies. Leveraging StrivePD, participants will use an iPhone and Apple Watch to track motor symptoms passively, including tremor and dyskinesia, along with self-reported activities like mood and medications, while completing remote surveys and rating scales on their health and Parkinson's symptoms. Through PD GENEration, participants will undergo genetic testing and counseling by providing a blood sample that will be used to test for clinically validated PD-related genetic variants. The study may help participants determine eligibility for genetically based clinical studies. 'We believe that there is significant potential to advance Parkinson's research by combining genetic insights with real-world data derived from AI-driven platforms like StrivePD to define disease subtypes. As trials become more precise, we can leverage data from this new study to reduce the noise, match patients to the right interventions, and generate stronger evidence to support the development of much-needed personalized treatments. If you carry a gene mutation, you shouldn't be treated like every other patient. This study could move us from 'average-patient' dosing to genome-matched therapy recommendations,' said Brian Pepin, CEO of Rune Labs. StrivePD closes the gap in Parkinson's care caused by infrequent specialist visits and unpredictable symptoms. Through AI-driven monitoring, the software care ecosystem combines Apple Watch data with the StrivePD app to track FDA-cleared metrics like tremor and dyskinesia, plus self-reported daily routines, to deliver real-time insights and proactive treatment guidance. By providing insights into symptoms at all hours of the day, StrivePD helps patients manage symptoms between visits, improve medication adherence, and avoid unnecessary ER trips, allowing them to take control of their disease and ease the pressure on the healthcare system. Using AI and extensive real-world patient data, StrivePD is also changing how neurological clinical trials are designed, helping improve predictive accuracy and reducing trial failures. PD GENEration from the Parkinson's Foundation is an international research initiative offering genetic testing and counseling at no cost to individuals diagnosed with PD. Since its inception in 2019, PD GENEration has enrolled over 24,000 people living with PD (PwP) across North, Central, and South America, the Caribbean, and Israel. PD GENEration's mission is to help PwP better understand their genetic link to PD and manage their PD treatment and care, contribute to the scientific understanding of PD now and into the future, and accelerate enrollment into clinical trials by empowering PwP and clinicians around the importance of genetics. 'We created PD GENEration to empower those with Parkinson's and their families to know more about their disease, accelerate clinical trials [that may one day halt Parkinson's], and drive forward research into the complex genetic factors that contribute to Parkinson's severity, progression, and treatment response,' said James Beck, PhD and Chief Scientific Officer of the Parkinson's Foundation. 'This new study with Rune Labs brings in powerful digital insights that can help us decode Parkinson's even further and speed up the path toward more effective treatments, and one day, a cure. Together, we can make better lives for those living with PD.' Initial genotype-response findings are expected in 2026, with anonymized results made available to researchers through the GP2 data repository to accelerate future studies. About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit and About Parkinson's Foundation The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $474 million in Parkinson's research and clinical care. Connect with us on Facebook, X, Instagram or call 1-800-4PD-INFO (1-800-473-4636). About the Global Parkinson's Genetics Program The Global Parkinson's Genetics Program (GP2) is an ambitious program focused on improving our understanding of the genetic architecture of the PD spectrum in a global context. This work will help address the most pressing needs of the global PD community, accelerating development and deployment of better PD therapies. GP2 is made up of member organizations around the world that are coming together to create a global research community. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Disease Research. About Parkinson's Disease Affecting an estimated one million Americans, Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson's and nearly 90,000 new cases are diagnosed each year in the U.S.
Yahoo
24-05-2025
- Sport
- Yahoo
Gary Payton admits he made mistakes when teaching his son how to play basketball: "I was thinking about myself, how I played, and I wanted him to play that way"
Like most fathers, Gary Payton wanted his son to be like him. But not only did he just want his namesake son to follow in his footsteps and become a professional basketball player, he wanted him to be the same player he was in the NBA. But living up to his father's name was like mission impossible for Gary II. His father was a nine-time NBA All-Star, nine-time All-NBA team selection, nine-time All-Defensive first team member, the 1996 NBA Defensive Player of the Year, and a member of the NBA's 75th Anniversary team. Advertisement Trying to dictate GP2's early basketball career caused a rift between father and son that almost derailed the younger Payton's basketball career. Ultimately, Gary Sr. realized that for his son to realize his full potential, he had to let him be himself. "At the first time that I was thinking of myself, how I played, and I wanted him to play that way. Y'all gotta understand man, there is only one Gary Payton, and that's me. I just named my son after me, that's it," he said. "So I told my son 'Look here man, I know you mad at me.' We got into a situation where our relationship wasn't really cool because of that." Gary didn't think GP2 would go to Oregon State According to the elder Payton, he tried to discourage GP2 the way his father did him. Early on, it looked like the pressure of living up to his name caught up with Gary II. However, by his junior year in HS, "The Young Glove" decided that he wasn't going to listen to the noise and was going to play his own game. Advertisement After high school, GP2 wanted to enroll at St. Mary's College in Moraga, California. However, his dad took him to Oregon State, where he once starred. At first, Gary thought his son would not take the challenge. But he did, and that was when the old man realized that his kid was no longer intimidated by his reputation. "When he made that decision to go to Oregon State behind me, that was a big deal for me because I really didn't think that he was going to do that. So I tell him all the time, I said 'Look here, Don't never think that you gotta be like me. It ain't going to work that way.' I said 'If you want to be like, be anything with me, just get your picture up a side of me. And let us be two legends together." The best thing about GP2 isn't even related to basketball GP2's number isn't retired by OSU like his dad's is. Unlike his father, who was the No.2 pick in the 1990 NBA Draft, his son took a longer route to the NBA after being undrafted in 2016. But while he hasn't been as good as his dad in the NBA, he's played nine seasons in the association and is coming off the second-best scoring year of his career in Golden State. That's impressive but it's not what makes Gary Sr. the proudest. Advertisement "The best thing I like about my kid is that when people come up to me, they don't talk about basketball. They talk about how good of a person he is, and how sweet he is. That makes a dad feel better because I know I did what I had to do as a parent," he added. Like all NBA dads, Gary was away most of the time because of his basketball career. But hearing people say nice things about GP2 as a person—"The Glove" says that's the best feeling for any father—and it's not even basketball-related. Related: "That is the worst basketball ever" - GP shares why constant switching on defense is a big problem in today's NBA
